<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865110</url>
  </required_header>
  <id_info>
    <org_study_id>MCL R2 Elderly</org_study_id>
    <nct_id>NCT01865110</nct_id>
  </id_info>
  <brief_title>R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL</brief_title>
  <official_title>Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance
      improves progression free survival (PFS) compared to standard rituximab maintenance after
      induction treatment consisting of R-CHOP + R-HAD vs R-CHOP alone in older patients (≥ 60
      year old) with mantle cell lymphoma.

      The treatments consist of two phases: induction treatment (3 R-CHOP21 + 3 cycles of R-HAD28
      alternating) vs 8 cycles of R-CHOP21) followed by maintenance treatment (13 cycles of
      rituximab + 26 cycles of lenalidomide vs 13 cycles of rituximab).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance
      improves progression free survival (PFS) compared to standard rituximab maintenance after
      induction treatment consisting of R-CHOP + R-HAD versus R-CHOP alone in older patients (≥ 60
      year old) with mantle cell lymphoma. 643 patients will be randomized in induction phase and
      433 in maintenance phase.

      The treatments consist of two phases:

        -  induction treatment will be 3 cycles of R-CHOP21 + 3 cycles of R-HAD28(alternating)
           versus 8 cycles of R-CHOP21 alone

        -  maintenance treatment will be 13 cycles of rituximab every 8 weeks + 26 cycles of
           lenalidomide every 4 weeks vs 13 cycles of rituximab every 8 weeks.

      Patients will be followed 2.5 years after the last patient randomized for maintenance for
      final analysis. All subjects who complete or discontinue the maintenance treatment for any
      reason will be followed for at least 3 years after his/her last study treatment
      administration in maintenance period for Second Primary Malignancies (SPM). A long term
      follow-up for progression/death will be done up to the end of period of SPM data collection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>2.5 years after last patient randomized in maintenance</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">633</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Induction experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standart induction arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 cycles of R-CHOP administered in 3 week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lenalidomide + rituximab : 13 cycles of rituximab 375 mg/m² administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance standart arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13 cycles of rituximab 375 mg/m² administered in 8 week cycles for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles</description>
    <arm_group_label>Standart induction arm</arm_group_label>
    <other_name>rituximab, CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP / R-HAD</intervention_name>
    <description>R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating</description>
    <arm_group_label>Induction experimental arm</arm_group_label>
    <other_name>rituximab, CHOP</other_name>
    <other_name>rituximab HD AraC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 750 mg every 8 weeks for 24 months</description>
    <arm_group_label>Maintenance experimental arm</arm_group_label>
    <arm_group_label>Maintenance standart arm</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months</description>
    <arm_group_label>Maintenance experimental arm</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Signed informed consent form Biopsy-proven MCL according to WHO classification

        ≥ 60 years of age and ineligible for autologous transplant Ann Arbor stage II-IV
        Previously untreated ECOG PS ≤ 2

        Male subjects must:

          -  agree to use a condom during sexual contact with a woman of childbearing potential,
             even if they have had a vasectomy, throughout lenalidomide therapy

          -  agree to not donate semen during lenalidomide therapy.

        All subjects must:

          -  have an understanding that the lenalidomide could have a potential teratogenic risk.

          -  agree to abstain from donating blood while taking lenalidomide therapy

          -  agree not to share study medication with another person.

          -  be counselled about pregnancy precautions and risks of foetal exposure.

        Additional criteria for randomization in maintenance phase:

          -  CR, CRu or PR after induction treatment, determined as per Cheson 1999 criteria

          -  During the run-in period of 6 months starting from the date of the first
             randomization in the trial: in case of direct randomization into maintenance phase,
             patient must have been treated in first line by 6-8 cycles of R-CHOP.

        Exclusion Criteria:

        Female of childbearing potential

        Any of the following laboratory abnormalities at diagnosis, if not related to lymphoma:

        Absolute neutrophils count &lt;1,000 /mm3 Platelet count &lt; 75,000/mm3 AST/SGOT or ALT/SGPT
        &gt;3.0 UNL Serum total bilirubin &gt; 1.5 ULN (except if due to Gilbert's syndrome) Calculated
        creatinine clearance (Cockcroft-Gault formula or MDRD) &lt; 30 mL / min Central Nervous
        System involvement by lymphoma Contraindication for medical DVT prophylaxis for patients
        at high risk for DVT

        Prior history of malignancies other than MCL unless the subject has been free of the
        disease for ≥ 5 years. Exceptions include the following:

          -  Basal cell carcinoma or Squamous cell carcinoma of the skin

          -  Carcinoma in situ of the cervix or of the breast

          -  Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b). Any
             serious medical condition, laboratory abnormality or psychiatric illness that would
             prevent the patient to receive the study medication as planned.

        Seropositivity for human immunodeficiency virus at study entry Seropositivity for
        hepatitis C virus at study entry,

        Active viral infection with hepatitis B virus at study entry:

          -  HBsAg positive

          -  HBsAg negative, anti-HBs positive and anti-HBc positive

        Uncontrolled illness including, but not limited to:

          -  Active infection requiring parenteral antibiotics.

          -  Uncontrolled diabetes mellitus

          -  Chronic symptomatic congestive heart failure (Class NYHA III or IV).

          -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6
             months

          -  Clinically significant cardiac arrhythmia that is symptomatic or requires treatment,
             or asymptomatic sustained ventricular tachycardia.

        Prior ≥ Grade 3 allergic hypersensitivity to thalidomide. Prior ≥ Grade 3 rash or any
        desquamating (blistering) rash while taking thalidomide.

        Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine
        antibodies.

        Subjects with ≥ Grade 2 neuropathy. Prior use of lenalidomide Participation in another
        clinical trial within three weeks before randomization in this study

        Additional criteria for randomization in maintenance phase:

          -  SD or PD after induction treatment determined as per Cheson 1999 criteria

          -  Patient treated by induction immuno-chemotherapy other than 6-8 cycle of R-CHOP21 or
             2-3 cycles of R-CHOP21 / 2-3 cycles of R-HAD28 (alternating)

          -  Patients with serious underlying medical conditions, which could impair the ability
             to receive maintenance treatment

          -  Calculated creatinine clearance of &lt; 30 mL / min

          -  ANC is &lt; 1,000 cells/mm³

          -  Platelet count is &lt; 50,000 cells/mm³
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dreyling, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MCL Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Ribrag, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna Cornelia Kluin-Nelemans, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MCL Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine STEPHAN</last_name>
    <phone>+33 4 72 66 93 33</phone>
    <email>christine.stephan@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>AMIENS Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Pierre MAROLLEAU</last_name>
    </contact>
    <investigator>
      <last_name>Jean Pierre MAROLLEAU, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre MOLES</last_name>
      <email>mpmoles@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre MOLES, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d Avignon - Hopital Henri Duffaut</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borhane SLAMA</last_name>
      <email>Bslama@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Borhane SLAMA, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne BANOS</last_name>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne BANOS, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean FONTAN</last_name>
      <email>jfontan@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean FONTAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abderrazak EL YAMANI</last_name>
      <email>elyamaa@ch-blois.fr</email>
    </contact>
    <investigator>
      <last_name>Abderrazak EL YAMANI, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier FITOUSSI</last_name>
      <email>o.fitoussi@bordeauxnord.com</email>
    </contact>
    <investigator>
      <last_name>Olivier FITOUSSI, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna SCHMITT</last_name>
      <email>a.schmitt@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anna SCHMITT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Dr Duchenne</name>
      <address>
        <city>BOULOGNE SUR MER Cedex</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bachra CHOUFI</last_name>
      <email>b.choufi@ch-boulogne.fr</email>
    </contact>
    <investigator>
      <last_name>Bachra CHOUFI, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian TEMPESCUL</last_name>
      <email>adrian.tempescul@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Adrian TEMPESCUL, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Pierre VILQUE</last_name>
    </contact>
    <investigator>
      <last_name>Jean Pierre VILQUE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret MACRO</last_name>
      <email>macro-m@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Margaret MACRO, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Chambéry</name>
      <address>
        <city>Chambery</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine SENECAL</last_name>
      <email>delphine.senecal@ch-chambery.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine SENECAL, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François BOUE</last_name>
      <email>francois.boue@abc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>François BOUE, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain GUIEZE</last_name>
      <email>rguieze@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Romain GUIEZE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Santé République</name>
      <address>
        <city>CLERMONT FERRAND Cedex 2</city>
        <zip>63050</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël FLEURY</last_name>
      <email>jfleury@polesanterepublique.com</email>
    </contact>
    <investigator>
      <last_name>Joël FLEURY, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien de Corbeil</name>
      <address>
        <city>Corbeil Essones</city>
        <zip>91108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand JOLY</last_name>
      <email>bertrand.joly@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand JOLY, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN</last_name>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS</last_name>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Michel PIGNON</last_name>
      <email>jean-michel.pignon@ch-dunkerque.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel PIGNON, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rémy GRESSIN</last_name>
      <email>rgressin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Rémy GRESSIN, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard</name>
      <address>
        <city>GRENOBLE Cedex 1</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David ASSOULINE</last_name>
      <email>d.assouline@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>David ASSOULINE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Départemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé MAISONNEUVE</last_name>
      <email>herve.maisonneuve@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé MAISONNEUVE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katell LE DÛ</last_name>
      <email>k.ledu@cjb72.org</email>
    </contact>
    <investigator>
      <last_name>Katell LE DÛ, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel LARIBI</last_name>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel LARIBI, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Lens</name>
      <address>
        <city>Lens</city>
        <zip>62300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela ROBU</last_name>
      <email>drobu@ch-lens.fr</email>
    </contact>
    <investigator>
      <last_name>Daniela ROBU, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Claude Hurriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER</last_name>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 8</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER</last_name>
      <email>emmanuelle.nicolas@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle NICOLAS- VIRELIZIER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reda BOUABDALLAH</last_name>
      <email>bouabdallahr@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Reda BOUABDALLAH, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamilé FRAYER</last_name>
      <email>j-frayfer@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jamilé FRAYFER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alina ZAMFIR</last_name>
      <email>a.zamfir@chr-metz-thionville.fr</email>
    </contact>
    <investigator>
      <last_name>Alina ZAMFIR, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Region d Annecy</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas DAGUINDAU</last_name>
      <email>ndaguindau@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas DAGUINDAU, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>MONTPELLIER Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON</last_name>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume CARTRON, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven LE GOUILL</last_name>
      <email>steven.legouill@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Steven LE GOUILL, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean François RAMEE</last_name>
    </contact>
    <investigator>
      <last_name>Jean François RAMEE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR de la Source</name>
      <address>
        <city>ORLEANS cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omar BENBRAHIM</last_name>
    </contact>
    <contact_backup>
      <email>omar.benbrahim@chr-orleans.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Omar BENBRAHIM, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard DELARUE</last_name>
      <email>richard.delarue@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Richard DELARUE, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zora MARJANOVIC</last_name>
      <email>zora.marjanovic@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Zora MARJANOVIC, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean GABARRE</last_name>
      <email>jean.gabarre@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean GABARRE, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine THIEBLEMONT</last_name>
      <email>catherine.thieblemont@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine THIEBLEMONT, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SAHNES</last_name>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence SANHES, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krimo BOUABDALLAH</last_name>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Krimo BOUABDALLAH, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles SALLES</last_name>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles SALLES, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain DELMER</last_name>
      <email>adelmer@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DELMER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry LAMY de la CHAPELL LAMY de la CHAPELLE</last_name>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry LAMY de la CHAPELLE, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé TILLY</last_name>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé TILLY, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Réda GARIDI</last_name>
      <email>r.garidi@ch-stquentin.fr</email>
    </contact>
    <investigator>
      <last_name>Réda GARIDI, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de la Loire</name>
      <address>
        <city>St priest en jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane MOUNIER</last_name>
      <email>christiane.mounier@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Christiane MOUNIER, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Matthieu FORNECKER</last_name>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Luc-Matthieu FORNECKER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucie OBERIC</last_name>
      <email>oberic.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Lucie OBERIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline DARTIGEAS</last_name>
      <email>c.dartigeas@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline DARTIGEAS, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIERRE FEUGIER</last_name>
      <email>p.feugier@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal GODMER</last_name>
      <email>pascal.godmer@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal GODMER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent RIBRAG</last_name>
      <email>vincent.ribrag@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent RIBRAG, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>RCHOP</keyword>
  <keyword>RHAD</keyword>
  <keyword>rituximab</keyword>
  <keyword>lenalidomide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
